Lynkuet is the first dual neurokinin receptor antagonist approved for moderate to severe VMS in menopause, offering a hormone-free treatment option. Phase III OASIS trials showed significant ...

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug ...

GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...

Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving ...

PE: Could DTC programs help simplify the drug-pricing system? O’Dell: I’m guessing that the pharmaceutical manufacturers are ...

The DTC model aligns with Most-Favored-Nation pricing, aiming to close the US drug price gap with other high-income countries ...

In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of BPD Healthcare to strengthen its health system reach, and ...

Elevara Medicines secured $70 million in Series A funding to advance ELV001's Phase II trial for rheumatoid arthritis and explore other chronic inflammatory conditions. Pharma investments surge as ...

The model imagines a new future in which traditional pharmacy distribution and access channels are bypassed.

Alkermes acquires Avadel for $2.1 billion, enhancing its sleep medicine market presence and commercial portfolio with Lumryz. The acquisition supports Alkermes' development pipeline for central ...

Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...